In an early trial of 61 patients with spreading cancer, the KRAS inhibitor daraxonrasib combined with chemotherapy halted tumour progression in 90% of participants. The combined regimen appeared to nearly double the duration of disease control, causing tumours to shrink or disappear in over 60% of cases. Scans showed no detectable disease in roughly one in 12 patients, offering an encouraging development for the common cancer with the lowest UK survival rate. However, doctors caution that the treatment is not a definitive cure because the disease can eventually return.
Key points
The medication functions by targeting and shutting off specific KRAS mutations that drive…: The medication functions by targeting and shutting off specific KRAS mutations that drive tumour growth in pancreatic, lung, and ovarian cancers.
Although the drug has secured approval in the United States, doctors emphasize that the t…: Although the drug has secured approval in the United States, doctors emphasize that the therapy remains a management tool rather than a cure.
Medical experts require longer clinical studies to establish whether the therapy can deli…: Medical experts require longer clinical studies to establish whether the therapy can deliver lasting remission beyond the initial year-and-a-half monitoring period.
Sources checked by our analysis pipeline: 1
- Published
Experts are calling it the biggest breakthrough in pancreatic cancer treatment for decades - a daily pill that appears to shrink and possibly even eliminate tumours in some patients with one of the deadliest and hardest-to-treat cancers.
Cancer became undetectable on scans in one in 12 of the patients given daraxonrasib along with chemotherapy in early medical trials.
Tumours stopped growing in almost all of the 61 participants who had recently been diagnosed with advanced pancreatic cancer that had spread to other parts of the body.
But doctors stress it is a long way from knowing how long it might keep the disease at bay and should not be seen as a cure.
Incredibly exciting
Cancer Research UK called it "the biggest leap forward in decades" for pancreatic cancer patients.
The charity's Dr Sam Godfrey told BBC News that the results were incredibly exciting. "What this new drug has done is it's found a way of drugging the undruggable.
"We are finally seeing progress in pancreatic cancer which is so long overdue."
University of California, Berkeley researchers have discovered that the molecule TOFA drives weight loss by raising energy expenditure instead of curbing appetite. This metabolic approach provides a critical alternative to popular therapies that frequently cause patients to lose significant lean muscle mass. If successfully translated to humans, the therapy could substantially improve outcomes for conditions like obesity, diabetes, and fatty liver disease.
Persistent regional outbreaks have stripped multiple nations of their measles-free designations, prompting renewed public health scrutiny regarding community protection levels. Despite the shift in national status, medical guidance confirms that standard two-dose regimens continue to offer lifelong defense for the general population. Additional immunization measures are strictly targeted at specific demographic cohorts and vulnerable individuals facing elevated exposure risks.
British Medical Association members in Northern Ireland are demanding full pay restoration to counter years of earnings erosion and worsening staff burnout. The industrial action arrives amid strict budget constraints at Stormont that currently prevent the local health department from funding even basic recommended increases. With senior medical colleagues staging a separate walkout days later, regional health services face severe winter capacity pressures and prolonged patient delays.